The Senate Judiciary Committee today voted 16-5 to approve the Creating and Restoring Equal Access to Equivalent Samples Act (S. 974). The AHA-supported bill would allow generic drug manufacturers facing certain anticompetitive delay tactics to bring an action in federal court for injunctive relief. More than 45 organizations, including the AHA, last week urged the committee to support the legislation to “end the anticompetitive abuses utilized by some brand-name manufacturers, help restore the balance between innovation and affordability that Congress intended, and achieve the goal of more affordable prescription drugs.” The Congressional Budget Office estimates the legislation will save $3.8 billion over 10 years.

Related News Articles

Headline
The Alliance for Addiction Payment Reform, whose members include the AHA, today showcased its value-based payment model for addiction and recovery support…
Headline
The AHA is engaging in early primary states, including Nevada and South Carolina, with ads about affordability and rural health care to ensure issues…
Headline
The House Ways and Means Committee today favorably reported out, as amended, the Consumer Protections Against Surprise Medical Bills Act (H.R. 5826), AHA-…
Headline
The Campaign for Sustainable Rx Pricing today launched an ad campaign calling for Congress to pass bipartisan legislation to “hold Big Pharma accountable…
Headline
The Department of Health and Human Services today issued a proposed rule intended to clarify the rights and obligations of faith-based organizations…
Headline
Kansas Gov. Laura Kelly has reached agreement with Senate Republicans on a bipartisan proposal to expand Medicaid eligibility to low-income uninsured…